Novo Nordisk

NICE shuns Novo Nordisk's obesity med Saxenda, citing CV questions
NICE shuns Novo Nordisk's obesity med Saxenda, citing CV questions
Fierce Pharma
Novo Nordisk
Saxenda
UK
NICE
Flag link:
Novo Nordisk’s quiet entry into the year of Alzheimer’s
Novo Nordisk’s quiet entry into the year of Alzheimer’s
EP Vantage
Novo Nordisk
Victoza
Alzheimer's disease
Flag link:
Novo Nordisk's diabetes pill Rybelsus to be covered by Express Scripts
Novo Nordisk's diabetes pill Rybelsus to be covered by Express Scripts
Reuters
Novo Nordisk
Rybelsus
Express Scripts
PBMs
Flag link:
Novo Nordisk's blockbuster Ozempic wins FDA label boost with CV indication
Novo Nordisk's blockbuster Ozempic wins FDA label boost with CV indication
Endpoints
Novo Nordisk
Ozempic
diabetes
cardiovascular events
FDA
Flag link:
FDA OKs Novo's Fiasp for diabetic children
FDA OKs Novo's Fiasp for diabetic children
Seeking Alpha
insulin
FDA
Novo Nordisk
Fiasp
pediatrics
diabetes
type 1 diabetes
Flag link:
Novo Nordisk Launches $99 Insulin Program
Novo Nordisk Launches $99 Insulin Program
BioSpace
Novo Nordisk
diabetes
insulin
drug pricing
Flag link:
Novo Nordisk joins with UVA in diabetes digital simulation project
Novo Nordisk joins with UVA in diabetes digital simulation project
Pharmaforum
Novo Nordisk
UVA
R&D
type 2 diabetes
Flag link:
ICER Warns of ‘Short-Term Budget Challenges’ with Novo’s Rybelsus
ICER Warns of ‘Short-Term Budget Challenges’ with Novo’s Rybelsus
Xtalks
Novo Nordisk
Rybelsus
oral semaglutide
diabetes
ICER
drug pricing
Flag link:
Novo Nordisk CEO Jørgensen aims to leverage diabetes know-how, deals into the new decade
Novo Nordisk CEO Jørgensen aims to leverage diabetes know-how, deals into the new decade
Fierce Pharma
Novo Nordisk
Lars Fruergaard Jorgensen
Pharma CEOs
diabetes
Flag link:
AZ, Merck and Novartis top Big Pharma's Q3 growth charts. Teva and Pfizer? Not so much
AZ, Merck and Novartis top Big Pharma's Q3 growth charts. Teva and Pfizer? Not so much
Fierce Pharma
earnings
Big Pharma
AstraZeneca
Merck
Celgene
Novartis
Novo Nordisk
Pfizer
Flag link:
Novo Ventures Sows $25M Into Accelerator to Break Into Illustrious Mass Bio Space
Novo Ventures Sows $25M Into Accelerator to Break Into Illustrious Mass Bio Space
Xconomy
Novo Ventures
Broad Institute
Harvard
biotech
accelerators
Massachusetts
Novo Nordisk
Flag link:
Dicerna scores broad, 'rest of liver' deal with Novo Nordisk, bagging $225M in cash to hit some 30 targets with RNAi platform
Dicerna scores broad, 'rest of liver' deal with Novo Nordisk, bagging $225M in cash to hit some 30 targets with RNAi platform
Endpoints
Dicerna
Novo Nordisk
liver disease
RNAi
Flag link:
Novo Nordisk buys rights to NASH drug from Japan’s UBE
Novo Nordisk buys rights to NASH drug from Japan’s UBE
Pharmaforum
Novo Nordisk
NASH
Japan
UBE
UD-014
Flag link:
Novo Nordisk (NVO) Q3 Earnings Beat Estimates, Revenues Miss
Novo Nordisk (NVO) Q3 Earnings Beat Estimates, Revenues Miss
Yahoo/Zacks.com
Novo Nordisk
earnings
Flag link:
Novo drops oral GLP-1 analog to focus on next-gen Rybelsus
Novo drops oral GLP-1 analog to focus on next-gen Rybelsus
Fierce Biotech
Novo Nordisk
diabetes
OG2023SC
Rybelsus
oral semaglutide
Flag link:
Why Novo Nordisk should buy Uniqure
Why Novo Nordisk should buy Uniqure
EP Vantage
Novo Nordisk
gene editing
hemophilia
uniQure
Bluebird Bio
Flag link:
Novo taps bluebird bio for gene-editing tech
Novo taps bluebird bio for gene-editing tech
Fierce Biotech
Novo Nordisk
Bluebird Bio
R&D
gene editing
hemophilia
Flag link:
Novo Nordisk announces obesity digital health tie-up with Noom
Novo Nordisk announces obesity digital health tie-up with Noom
Pharmaforum
Novo Nordisk
Noom
digital health
obesity
Flag link:
Mom approved: J&J, Takeda and more lead Working Mother's best places to work list for 2019
Mom approved: J&J, Takeda and more lead Working Mother's best places to work list for 2019
Fierce Pharma
JNJ
Takeda
parents
Eli Lilly
Merck
Novo Nordisk
Sanofi
Flag link:
How Big Can This $8 Billion-Plus Diabetes Drug Class Get?
How Big Can This $8 Billion-Plus Diabetes Drug Class Get?
Motley Fool
diabetes
Eli Lilly
Merck
Novo Nordisk
GSK
Byetta
Victoza
Bydureon
Ozempic
Tanzeum
Trulicity
Rybelsus
Flag link:

Pages